Navigation Links
Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
Date:1/9/2014

61% of the subjects taking NBI-98854 were "much improved" or "very much improved" at Week 12.  The twelve-week treatment period was followed by a four-week washout period.  At the end of this washout period, only 29% of these same subjects were evaluated by the treating physicians as "much improved" or "very much improved" utilizing the CGI-TD.

"This twelve-week safety and related efficacy data is another important component for our End of Phase II FDA meeting that we plan to request during the first half of 2014," said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences.

Subject Profile

The Kinect study randomized 109 subjects; 81 subjects completed Week 12, of which 42  subjects were originally randomized to placebo and 39 were originally randomized to NBI-98854.  Similar to the Company's other studies, the average age of the trial participants was 55 years with an average age at onset of tardive dyskinesia of 47 years.  Approximately two-thirds of the subjects were male.

Kinect Study Design

The Kinect study was a randomized, parallel, double-blind, placebo-controlled, Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with underlying schizophrenia or schizoaffective disorder.  The study assessed two doses of once-daily NBI-98854 over a six-week placebo-controlled dosing period.  Half of the randomized subjects received placebo and half received one of two doses of NBI-98854.  The two NBI-98854 dosing groups consisted of a 50mg group for six weeks and a group that began at 100mg for the initial two weeks then converted to 50mg for the final four weeks of the placebo-controlled dosing period.  Subsequent to the placebo-controlled dosing, all subjects were eligible to enter a six-week open-label safety extension of 50mg of NBI-98854 administered once daily with additional A
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... WASHINGTON , July 23, 2014  Nearly 8,000 ... for Cardinal Health,s annual Retail Business Conference (RBC), ... & Convention Center. This year,s event encourages pharmacists to ... in their communities and for their future. ... pharmacy owners to network with their peers and learn ...
(Date:7/23/2014)... July 23, 2014  The management team at ... will hold a conference call on July 31, ... quarter ended June 30, 2014.  The call details ... , 8:30 am EDTDial-in numbers: , Toll free: ... 317-0790Webcast (live & archive): , www.columbialabs.com , ...
(Date:7/23/2014)... , July 23, 2014 This September ... in Las Vegas for ... by educator, author, forward thinker and private practitioner Dr. ... experts together to candidly discuss clinical and practice management ... event is a unique opportunity to welcome fresh thinking ...
Breaking Medicine Technology:Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3
... FOUNTAIN HILLS, Ariz., Sept. 23 Sunridge International ... today that it has shipped its first order ... for several Middle Eastern countries.  AME plans to ... throughout the region, while simultaneously conducting a short ...
... 23 Reportlinker.com announces that a new market ... Bayer Schering Pharma AG: PharmaVitae Profile ... Introduction This analysis examines the historical ... prescription pharma sector. The profile encompasses global company ...
Cached Medicine Technology:Sunridge Ships First Order to the Middle East 2Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile 2Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile 3Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile 4Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile 5Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile 6
(Date:7/23/2014)... patients arriving at the emergency department, the drug ... for rapid, life-saving intubation, despite decades-old studies that ... of a systematic review of 10 recent studies ... "wonder drug" are published online in Annals ... Ketamine on Intracranial and Cerebral Perfusion Pressure and ...
(Date:7/23/2014)... 23, 2014 AidJoy is delighted to announce ... Zen on September 5, 2014 from 7:00 to ... supporters are expected to attend this semi-formal event. , "We ... the past six years," says Jess Dennis, Director of Operations ... reflect on this moment in AidJoy’s history before we launch ...
(Date:7/23/2014)... Dallas, Texas (PRWEB) July 23, 2014 ... to 2020?, provides key market data on the ... provides value, in millions of US dollars, and ... US dollars), within market categories Cardiac Valve Repairs ... company shares and distribution shares data for each ...
(Date:7/23/2014)... (July 23, 2014) Statins, a class of drugs ... patient,s risk of developing Barrett,s esophagus, according to a ... , the official journal of the American Gastroenterological Association. ... with statin use. , "Patients who received statins had ... Barrett,s esophagus compared to non-users," said study author Hashem ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 With ... the leasing and financing company LeaseQ announced that ... server based software sector, they still see robust ... , To learn more about technology equipment leasing, ... and CEO of LeaseQ was quoted as saying, ...
Breaking Medicine News(10 mins):Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 2Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 3Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 4Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 5Health News:Statin use decreases the risk of Barrett's esophagus 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 3
... Osteoporosis Foundation has estimated that nearly 55 percent of ... a disease of porous and brittle bones// that causes ... among Americans has been found to contribute to lower ... conducted by Katherine Tucker, PhD, director of the Epidemiology ...
... lasting modifications in the brain metabolism and blood flow ... confusion in several cancer survivors. , ,The ... Los Angeles, revealed inferior metabolism in the important region ... chemotherapy 5-10 years ago.,A spike in blood flow to ...
... declared as Breast Cancer Awareness Month and with that ... shops//. The campaign for raising funds towards breast ... cosmetics and teddy bears, as well as major charity ... ,The Boobie-Thon that has been running annually for ...
... against polio is far from over in Bihar with the ... covered in the June-July immunisation drive this year//. ,Eight ... the drive.Two new polio cases were detected in Jehanand, while ... district has also four new cases of polio, an official ...
... cancer, such as radiotherapy, surgery and drugs as well ... vary throughout the EU, according to a study published ... 3 October 2006. Access to information is also said ... survey published in Medical OncologyStatus in Europe is a ...
... children need an hour of daily physical exercise for their ... at Glasgow University studied 545 children at 36 nurseries in ... the recommended adult level of exercise - 30 minutes, three ... ,But this activity was not enough to affect ...
Cached Medicine News:Health News:Consumption of Colas Increase Risk of Osteoporosis in Older Women 2Health News:Consumption of Colas Increase Risk of Osteoporosis in Older Women 3Health News:Chemotherapy causes mental fog 2Health News:All in the Name of ‘Breast Cancer Awareness 2
Coronary angiographic catheter...
The entirely open modular system is especially suitable for stereotactic microsurgical procedures....
Used to negotiate tortuous vessels....
The Emerald Guidewire is intended for percutaneous introduction of catheters....
Medicine Products: